<DOC>
	<DOCNO>NCT02489669</DOCNO>
	<brief_summary>The urine flow rate ( UFR ) -guided left-ventricular end-diastolic pressure ( LVEDP ) -guided hydration regimen propose prevent contrast-induced acute kidney injury ( CI-AKI ) . The REnal Insufficiency Following Contrast MEDIA Administration TriaL III ( REMEDIAL III ) trial randomize , multicenter , investigator-sponsored trial aim compare 2 hydration strategy high risk patient . Patients estimate glomerular filtration rate &lt; 45 ml/min/1.73 m2 and/or high risk CI-AKI ( define accord Mehran 's score ≥11 and/or Gurm 's score &gt; 7 ) enrol . Patients divide high ( &gt; 12 mm Hg ) normal LVEDP , non-invasively estimate transmitral flow velocity annular velocity ratio ( E/E ' index ) . Patients group randomly assign 1 ) LVEDP-guided hydration normal saline ( LVEDP-guided group ) . The fluid infusion rate adjust accord LVEDP follow : 5 mL/kg/hr LVEDP &lt; 12 mmHg ; 3 mL/kg/hr 13-18 mmHg ; 1.5 mL/kg/hr &gt; 18 mmHg . 2 ) UFR-rate guide hydration ( RenalGuard group ) . In group , hydration normal saline plus low-dose furosemide control RenalGuard system , order reach maintain high ( &gt; 300 mL/h ) UFR . In case iobitridol ( low-osmolar , non ionic contrast agent ) administer . The primary endpoint composite CI-AKI ( i.e. , serum creatinine increase ≥ 25 % ≥ 0.5 mg/dl baseline value 48 hour contrast medium exposure ) and/or acute pulmonary edema .</brief_summary>
	<brief_title>Renal Insufficiency Following Contrast Media Administration Trial III</brief_title>
	<detailed_description>Contrast-induced acute kidney injury ( CI-AKI ) powerful predictor unfavorable early late outcome . Hydration represent cornerstone CI-AKI prevention1 . However , present consensus hydration carry . The recommended hydration regimen normal saline infusion 1 mL/kg/h 12 hour 12 hour CM exposure . Limitations hydration regimen include 1 ) preclusion urgent/emergent setting , 2 ) suboptimal efficacy high- high risk patient . Indeed , high very-high risk patient rate CI-AKI may still high , whereas force hydration regimen may increase risk pulmonary edema . In order clarify carry optimal hydration , 2 regimen recently propose : 1 ) leave ventricular end-diastolic pressure ( LVEDP ) -guided hydration 2 ) urine flow rate ( UFR ) -guided hydration . The POSEIDON trial demonstrate leave ventricular end-diastolic pressure ( LVEDP ) -guided hydration superior conventional hydration regimen prevent CI-AKI . In LVEDP-guided hydration , fluid infusion rate adjust accord LVEDP follow : 5 mL/kg/hr LVEDP &lt; 12 mmHg ; 3 mL/kg/hr 13-18 mmHg ; 1.5 mL/kg/hr &gt; 18 mmHg . The reported rate pulmonary edema 1.5 % . Another theory CI-AKI prophylaxis suggest induction maintenance high UFR . This high UFR allow body rapidly eliminate contrast medium , reduce contact time within nephron . The RenalGuard™ System ( PLC Medical Systems , Inc. ) combination limit ( 0.25 mg/kg ) dose furosemide induces maintain high UFR ( &gt; 300 mL/h ) safely maintain intravascular blood volume minimize risk under-hydration . Furthermore , report rate pulmonary edema &lt; 1 % . The purpose present study compare LVEDP-guided hydration UFR-guided hydration patient high risk CI-AKI . Following enrollment , LVEDP non-invasively estimate transmitral flow velocity annular velocity ratio ( E/E ' index ) . Estimated LVEDP pressure &gt; 12 mm Hg consider high . Therefore , accord estimate LVEDP value , patient stratify high LVEDP normal LVEDP group . After stratification , patient randomly assign one follow treatment : 1 ) LVEDP-guided group , 2 ) RenalGuard group . Patients allocate group receive intravenous 0.9 % sodium chloride least one hour prior cardiac catheterization . In group fluid rate adjust accord non-invasive LVEDP estimate follow : 5 mL/kg/hr LVEDP ≤12 mmHg ; 3 mL/kg/hr 13-18 mmHg ; 1.5 mL/kg/h &gt; 18 mmHg , suggest POSEIDON trial . Invasive LVEDP measurement also estimate patient place angle 5 6-French pigtail catheter mid-cavity leave ventricle begin procedure contrast medium injection order confirm non-invasive estimate value . In high LVEDP group , sample size calculate demonstrate superiority RenalGuard therapy LVEDP-guided hydration regimen . The investigator expect reduction primary composite endpoint 15 % LVEDP-guided group 8 % RenalGuard group . Using two-sided Chi-square test significance level 0.05 , total least 644 randomized patient ( 322 arm ) afford study 80 % power . According previous data , high LVEDP expect approximately 50 % recruited patient . Serum creatinine , cystatin C , blood urea nitrogen , sodium potassium measure day , 12 , 24 , 48 hour 1 week administration contrast agent ; additional measurement perform case deterioration baseline renal function . CI-AKI define increase serum creatinine &gt; =0.3 mg/dl 48 hour contrast medium exposure . Patient demographic detail , medical history , current medication , eGFR , risk score CI-AKI , leave ventricular ejection fraction record baseline . Total hydration volume administer accord prophylaxis 24 48 hour follow procedure well total urine volume record . The pre-procedure sCr level consider sCr concentration initiation prophylaxis . End-point data adverse event collect in-hospital stay 1-month . Six-month 12-month MAE also collect . All adverse event record case report form data coordinate center inform facsimile within 72 hour event . Serious event safety issue review independent Data Monitoring Safety Committee . All event adjudicate Clinical Events Committee ( CEC ) , blind treatment assignment . At least 2 member CEC review clinical data relevant documentation determine whether end point occur accord study definition . In case disagreement reviewer , third member CEC adjudicate data consider entire committee 2 3 reviewer agree . In normal LVEDP group , sample size calculated demonstrate non-inferiority primary composite endpoint RenalGuard group versus LVEDP-guided group . Expecting 7 % primary endpoint rate RenalGuard group 9 % LVEDP-guided group , use two-sided Chi-square test significance level 0.05 2 % non-inferiority margin , total least 628 randomized patient ( 364 arm ) afford study 80 % power .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>All consecutive patient chronic kidney disease ( CKD ) schedule coronary and/or peripheral angiography and/or angioplasty eGFR &lt; 45 ml/min/1.73 m2 and/or At high risk CIAKI accord Mehran 's score ≥11 and/or Gurm 's score &gt; 7 Age &lt; 18 year Women pregnant Acute pulmonary edema Acute myocardial infarction Recent contrast medium exposure Endstage CKD chronic dialysis Multiple myeloma Current enrolment study enrolment REMEDIAL III would involve deviation either protocol Cardiogenic shock Administration theophilline , dopamine , mannitol fenoldopam</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>